The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Dec 18

PMID 33333850

Citations 14

Authors

Katrine D Galsgaard

Affiliations

Soon will be listed here.

Abstract

A key criterion for the most common chronic liver disease-non-alcoholic fatty liver disease (NAFLD)-is an intrahepatic fat content above 5% in individuals who are not using steatogenic agents or having significant alcohol intake. Subjects with NAFLD have increased plasma concentrations of glucagon, and emerging evidence indicates that subjects with NAFLD may show hepatic glucagon resistance. For many years, glucagon has been thought of as the counterregulatory hormone to insulin with a primary function of increasing blood glucose concentrations and protecting against hypoglycemia. However, in recent years, glucagon has re-emerged as an important regulator of other metabolic processes including lipid and amino acid/protein metabolism. This review discusses the evidence that in NAFLD, hepatic glucagon resistance may result in a dysregulated lipid and amino acid/protein metabolism, leading to excess accumulation of fat, hyperglucagonemia, and increased oxidative stress contributing to the worsening/progression of NAFLD.

Citing Articles

Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet.

Galsgaard K, Elmelund E, Hunt J, Smits M, Grevengoed T, Christoffersen C Physiol Rep. 2025; 13(4):e70235.

PMID: 39985139 PMC: 11845321. DOI: 10.14814/phy2.70235.

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.

Associations between circulating amino acids and metabolic dysfunction-associated steatotic liver disease in individuals living with severe obesity.

Maltais-Payette I, Bourgault J, Gauthier M, Biertho L, Marceau S, Julien F Physiol Rep. 2025; 13(3):e70171.

PMID: 39868884 PMC: 11770886. DOI: 10.14814/phy2.70171.

The steroid hormone 20-hydroxyecdysone induces lipophagy via the brain-adipose tissue axis by promoting the adipokinetic hormone pathway.

Li Y, Li Y, Wang X, Liu T, Dong D, Wang J J Biol Chem. 2025; 301(2):108179.

PMID: 39798879 PMC: 11835591. DOI: 10.1016/j.jbc.2025.108179.

Elevated glucagon and postprandial hyperglycemia in fatty liver indicate early glucose intolerance in metabolic dysfunction associated steatotic liver disease.

Oikawa R, Nakanishi Y, Fujimoto K, Wakasa A, Iwadare M, Iwao H Sci Rep. 2024; 14(1):29916.

PMID: 39623059 PMC: 11612171. DOI: 10.1038/s41598-024-81663-w.

References

ASHFORD T, PORTER K . Cytoplasmic components in hepatic cell lysosomes. J Cell Biol. 1962; 12:198-202. PMC: 2106008. DOI: 10.1083/jcb.12.1.198. View

Dresler C, Fortner J, McDermott K, Bajorunas D . Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 1991; 214(2):131-40. PMC: 1358512. DOI: 10.1097/00000658-199108000-00007. View

Charbonneau A, Unson C, Lavoie J . High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J Physiol. 2006; 579(Pt 1):255-67. PMC: 2075374. DOI: 10.1113/jphysiol.2006.121954. View

Liang Y, Osborne M, Monia B, Bhanot S, Gaarde W, Reed C . Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004; 53(2):410-7. DOI: 10.2337/diabetes.53.2.410. View

Doi K, KUROSHIMA A . Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats. Life Sci. 1982; 30(9):785-91. DOI: 10.1016/0024-3205(82)90614-2. View

Shah P, Vella A, Basu A, Basu R, Schwenk W, Rizza R . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85(11):4053-9. DOI: 10.1210/jcem.85.11.6993. View

Bell G, Laybourn P, Najarian R . Exon duplication and divergence in the human preproglucagon gene. Nature. 1983; 304(5924):368-71. DOI: 10.1038/304368a0. View

Nair K, Halliday D, Matthews D, Welle S . Hyperglucagonemia during insulin deficiency accelerates protein catabolism. Am J Physiol. 1987; 253(2 Pt 1):E208-13. DOI: 10.1152/ajpendo.1987.253.2.E208. View

Wewer Albrechtsen N, Pedersen J, Galsgaard K, Winther-Sorensen M, Suppli M, Janah L . The Liver-α-Cell Axis and Type 2 Diabetes. Endocr Rev. 2019; 40(5):1353-1366. DOI: 10.1210/er.2018-00251. View

10.

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

11.

Deter R, Baudhuin P, DE DUVE C . Participation of lysosomes in cellular autophagy induced in rat liver by glucagon. J Cell Biol. 1967; 35(2):C11-6. PMC: 2107130. DOI: 10.1083/jcb.35.2.c11. View

12.

Hansen M, Rubinsztein D, Walker D . Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol. 2018; 19(9):579-593. PMC: 6424591. DOI: 10.1038/s41580-018-0033-y. View

13.

Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Patel H . Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease. Cardiovasc Hematol Agents Med Chem. 2018; 16(1):35-43. DOI: 10.2174/1871525716666180118152158. View

14.

Finan B, Yang B, Ottaway N, Smiley D, Ma T, Clemmensen C . A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2014; 21(1):27-36. DOI: 10.1038/nm.3761. View

15.

Boden G, Rezvani I, Owen O . Effects of glucagon on plasma amino acids. J Clin Invest. 1984; 73(3):785-93. PMC: 425081. DOI: 10.1172/JCI111272. View

16.

Marchetti P, Lupi R, Bugliani M, Kirkpatrick C, Sebastiani G, Grieco F . A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012; 55(12):3262-72. DOI: 10.1007/s00125-012-2716-9. View

17.

Ezaki J, Matsumoto N, Takeda-Ezaki M, Komatsu M, Takahashi K, Hiraoka Y . Liver autophagy contributes to the maintenance of blood glucose and amino acid levels. Autophagy. 2011; 7(7):727-36. PMC: 3149698. DOI: 10.4161/auto.7.7.15371. View

18.

Holst J, Wewer Albrechtsen N, Pedersen J, Knop F . Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis. Diabetes. 2017; 66(2):235-240. DOI: 10.2337/db16-0994. View

19.

Whalley N, Pritchard L, Smith D, White A . Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?. J Endocrinol. 2011; 211(1):99-106. DOI: 10.1530/JOE-11-0094. View

20.

Guettet C, Mathe D, Riottot M, Lutton C . Effects of chronic glucagon administration on cholesterol and bile acid metabolism. Biochim Biophys Acta. 1988; 963(2):215-23. DOI: 10.1016/0005-2760(88)90283-4. View